Women with T1-2 (≤3 cm) N0 breast cancer with an HER2+ disease undergoing neoadjuvant HER2-based targeted therapy who have a pathologic complete response after breast-conserving surgery will be randomized to receive either postoperative radiation or no radiation. Here, ERBB2 is linked to breast carcinoma.